The treatment landscape of Alzheimer’s disease (AD) is rapidly evolving, moving beyond purely symptomatic therapy towards earlier diagnosis and disease-modifying approaches.​

This shift highlights the growing importance of early recognition of mild cognitive impairment, timely referral for biomarker confirmation, and shared decision-making regarding emerging therapies. ​

This session will provide a practical overview of current treatment options, patient selection, safety considerations, and how primary care can integrate into this new, biomarker-driven model of Alzheimer’s disease management.